Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-tumor combined drug and use thereof in preparing anti-cancer drug

An anticancer drug and antitumor technology, applied in the field of biomedicine

Active Publication Date: 2017-11-24
SICHUAN JIUZHANG BIO TECH CO LTD
View PDF3 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The technical solution of the present application can solve the defects of drug resistance and various toxic and side effects of VEGF tyrosine kinase inhibitors due to long-term use or frequent use, improve the targeting of VEGF pathway inhibitors, reduce toxic and side effects, and improve patient compliance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-tumor combined drug and use thereof in preparing anti-cancer drug
  • Anti-tumor combined drug and use thereof in preparing anti-cancer drug
  • Anti-tumor combined drug and use thereof in preparing anti-cancer drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Example 1 MTT determination of proliferation inhibition of combination medication

[0035] 1.1 Materials and instruments

[0036] Tested drugs: chlorogenic acid, sorafenib, sunitinib, axitinib, pazopanib, bevacizumab.

[0037] Test cell lines: human lung cancer cell line A549, human kidney cancer cell line 786-0, human normal lung epithelial cell BEAS-2B, human embryonic kidney normal cell CCC-HEK-1

[0038] 1.2 Experimental method

[0039] Take a bottle of logarithmic growth phase tumor cells, wash twice with PBS, digest with 0.25% trypsin, and make a single cell suspension with RPMI-1640 culture medium containing 10% calf serum for counting. Inoculate 100μl of cells on 96-well culture plate under aseptic conditions, and the number of inoculated cells is 5xl0 3 / hole. Cells at 37℃, 5% CO 2 After 24h incubation in the incubator, the medium was changed.

[0040] The cells were divided into negative control group, single medication group, chlorogenic acid group and combination med...

Embodiment 2

[0061] Example 2 Anti-tumor animal test of combination medication

[0062] 2.1 Materials and methods

[0063] Test drugs: chlorogenic acid; VEGFR tyrosine kinase inhibitors: sorafenib, sunitinib, axitinib, pazopanib, bevacizumab

[0064] Test cell lines: lung cancer cell line A549 cells, human kidney cancer cell line 786-0

[0065] Tested animal: BABL / C-nu mouse, ♀, weighing 18-22g;

[0066] 2.2 Test method

[0067] 2.2.1 Establishment of experimental animal tumor model

[0068] Collect the logarithmic growth phase cells, centrifuge at 1000 rpm for 5 min, wash the cell sediment with PBS twice, after counting, adjust the cell concentration to 1x10 with serum-free medium 7 / m1, sent to the animal room under aseptic conditions. Under sterile experimental conditions, 1x10 was injected subcutaneously into the right armpit of the mouse 7 / m1 cells, 0.1ml each, obvious skin hills appeared in the injection area, and a large rice nodule appeared on the left axillary of the mouse one week later, i...

Embodiment 3

[0104] Example 3 Animal test of chlorogenic acid in the preparation of anti-multidrug resistance combination drugs

[0105] 3.1 Materials and methods

[0106] Test drug: chlorogenic acid; VEGF tyrosine kinase inhibitor: sorafenib, pazopanib.

[0107] Tested cell line: lung cancer drug-resistant cell line A549. The A549 cell line was induced by the sorafenib concentration gradient method, and established after clonal screening, and cultured before the experiment.

[0108] The human renal cancer drug-resistant cell line 786-0 was induced by the pazotinib concentration gradient method to induce the A549 cell line, which was established through clonal screening and cultured before the experiment.

[0109] Tested animal: BABL / C-nu mouse, ♀, weighing 18-22g;

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an anti-tumor combined drug and use thereof in preparing an anti-cancer drug. The combined drug comprises 10-40 weight parts of a first preparation and 2-100 weight parts of a second preparation. The invention further discloses use of chlorogenic acid in preparing an anti-cancer drug toxic and side effect inhibitor, and the anti-cancer drug is a VEGF channel inhibitor. According to the technical scheme adopted by the invention, targeting ability, to lung cancer and kidney cancer, of the VEGF channel inhibitor can be improved, and the toxic and side effect of the VEGF channel inhibitor can be reduced; and moreover, drug resistance of a VEGF tyrosine kinase inhibitor further can be reversed.

Description

Technical field [0001] The invention relates to the field of biomedicine, in particular to an anti-tumor combined drug and its use in preparing anti-cancer drugs. Background technique [0002] Chlorogenic acid is a carboxyphenolic acid composed of caffeic acid and quinic acid. The structure is as follows [0003] [0004] Chlorogenic acid has a wide range of pharmacological effects, including anti-oxidation, antibacterial and anti-inflammatory, anti-tumor, hepatoprotective, choleretic, blood circulation and blood pressure and other biological activities. [0005] Tumors are one of the main diseases that endanger human health today and seriously threaten human life. Most human tumors are solid tumors. Angiogenesis is a necessary condition for the growth and metastasis of solid tumor cells. Angiogenesis can provide more for tumor cells. Therefore, preventing the formation of tumor vascular network can make the tumor smaller and prevent tumor metastasis. [0006] Angiogenesis is mainly...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/216A61K45/06A61K31/44A61K31/404A61K31/4439A61K31/506A61P35/00
CPCA61K31/216A61K31/404A61K31/44A61K31/4439A61K31/506A61K45/06A61K2300/00
Inventor 张洁黄望杨华蓉张梦甜
Owner SICHUAN JIUZHANG BIO TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com